{"id":"placebo-to-linagliptin","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Muscle pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Linagliptin works by blocking the action of DPP-4, an enzyme that breaks down incretin hormones. This leads to an increase in the levels of incretin hormones, which in turn stimulates the release of insulin from the pancreas in a glucose-dependent manner. As a result, blood glucose levels are lowered.","oneSentence":"Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones, thereby enhancing glucose-dependent insulin secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:44.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04670666","phase":"PHASE3","title":"Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus","status":"RECRUITING","sponsor":"EMS","startDate":"2024-11-18","conditions":"Type 2 Diabetes Mellitus","enrollment":270},{"nctId":"NCT01734785","phase":"PHASE3","title":"Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-02-08","conditions":"Diabetes Mellitus, Type 2","enrollment":607},{"nctId":"NCT03429543","phase":"PHASE3","title":"Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-03-20","conditions":"Diabetes Mellitus, Type 2","enrollment":175},{"nctId":"NCT05886088","phase":"PHASE3","title":"Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"EMS","startDate":"2024-02","conditions":"Type 2 Diabetes Mellitus","enrollment":597},{"nctId":"NCT04564872","phase":"PHASE3","title":"HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sichuan Haisco Pharmaceutical Group Co., Ltd","startDate":"2020-11-13","conditions":"Diabetes Mellitus, Type 2","enrollment":465},{"nctId":"NCT04662866","phase":"PHASE2","title":"Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2021-02-10","conditions":"Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders","enrollment":64},{"nctId":"NCT02897349","phase":"PHASE3","title":"Linagliptin Add-on to Insulin Background Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-09-30","conditions":"Diabetes Mellitus, Type 2","enrollment":206},{"nctId":"NCT01243424","phase":"PHASE3","title":"CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-11-11","conditions":"Diabetes Mellitus, Type 2","enrollment":6103},{"nctId":"NCT02453555","phase":"PHASE3","title":"Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-05-14","conditions":"Diabetes Mellitus, Type 2","enrollment":275},{"nctId":"NCT02489968","phase":"PHASE3","title":"Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-05-12","conditions":"Diabetes Mellitus, Type 2","enrollment":880},{"nctId":"NCT02974504","phase":"PHASE4","title":"Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-09","conditions":"Type2 Diabetes","enrollment":207},{"nctId":"NCT02240680","phase":"PHASE4","title":"Linagliptin as Add on to Basal Insulin in the Elderly","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-09-23","conditions":"Diabetes Mellitus, Type 2","enrollment":302},{"nctId":"NCT02183324","phase":"PHASE2","title":"BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-02","conditions":"Diabetes Mellitus, Type 2","enrollment":72},{"nctId":"NCT02180334","phase":"PHASE4","title":"The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-07","conditions":"Diabetes Mellitus, Type 2","enrollment":12},{"nctId":"NCT01792518","phase":"PHASE3","title":"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-02","conditions":"Diabetes Mellitus, Type 2","enrollment":360},{"nctId":"NCT01969084","phase":"PHASE4","title":"The Effect of Linagliptin on Mitochondrial and Endothelial Function","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2013-10","conditions":"Type II Diabetes Mellitus","enrollment":45},{"nctId":"NCT01342484","phase":"PHASE2","title":"Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-04","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT01778049","phase":"PHASE3","title":"Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-01","conditions":"Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT02725502","phase":"NA","title":"Incretin Axis in Type 1 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2013-07","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT01968044","phase":"PHASE3","title":"A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-10","conditions":"Type 2 DM Patients With Moderate or Severe Renal Impairment","enrollment":132},{"nctId":"NCT02401880","phase":"PHASE4","title":"Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2015-05","conditions":"Type 2 Diabetes Mellitus","enrollment":89},{"nctId":"NCT01422876","phase":"PHASE3","title":"Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1405},{"nctId":"NCT02376075","phase":"PHASE3","title":"Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria","status":"COMPLETED","sponsor":"ikfe-CRO GmbH","startDate":"2013-01","conditions":"Arterial Hypertension, Albuminuria","enrollment":43},{"nctId":"NCT01703286","phase":"PHASE1","title":"Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-10","conditions":"Diabetes Mellitus, Type 2","enrollment":42},{"nctId":"NCT01438814","phase":"PHASE4","title":"Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-11","conditions":"Diabetes Mellitus, Type 2","enrollment":689},{"nctId":"NCT02183311","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-06","conditions":"Healthy","enrollment":56},{"nctId":"NCT00309608","phase":"PHASE2","title":"Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Diabetes Mellitus, Type 2","enrollment":333},{"nctId":"NCT02183298","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-05","conditions":"Healthy","enrollment":36},{"nctId":"NCT02173665","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-10","conditions":"Healthy","enrollment":64},{"nctId":"NCT01012037","phase":"PHASE2","title":"Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":491},{"nctId":"NCT01087502","phase":"PHASE3","title":"Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-03","conditions":"Diabetes Mellitus, Type 2","enrollment":241},{"nctId":"NCT00740051","phase":"PHASE3","title":"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-08","conditions":"Diabetes Mellitus, Type 2","enrollment":227},{"nctId":"NCT01512979","phase":"PHASE4","title":"Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-01","conditions":"Diabetes Mellitus, Type 2","enrollment":316},{"nctId":"NCT00800683","phase":"PHASE3","title":"Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-12","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT02097342","phase":"PHASE4","title":"Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus, Insulin Sensitivity/Resistance","enrollment":30},{"nctId":"NCT00602472","phase":"PHASE3","title":"BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1058},{"nctId":"NCT00641043","phase":"PHASE3","title":"Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-03","conditions":"Diabetes Mellitus, Type 2","enrollment":389},{"nctId":"NCT00622284","phase":"PHASE3","title":"Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1560},{"nctId":"NCT00798161","phase":"PHASE3","title":"Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-12","conditions":"Diabetes Mellitus, Type 2","enrollment":857},{"nctId":"NCT00601250","phase":"PHASE3","title":"Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-01","conditions":"Diabetes Mellitus, Type 2","enrollment":701},{"nctId":"NCT00654381","phase":"PHASE3","title":"Japanese P III vs Voglibose and Placebo","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2","enrollment":561},{"nctId":"NCT00954447","phase":"PHASE3","title":"Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1263}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Linagliptin","genericName":"Placebo to Linagliptin","companyName":"LG Life Sciences","companyId":"lg-life-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones, thereby enhancing glucose-dependent insulin secretion. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}